Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 655

Results For "ED"

7998 News Found

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines
Biotech | March 01, 2022

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry


USFDA approves CITI Biopharma’s Vonjo
Drug Approval | March 01, 2022

USFDA approves CITI Biopharma’s Vonjo

Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients


AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Biotech | March 01, 2022

AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006

Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m


South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
Biotech | March 01, 2022

South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical

Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical


Thermo Fisher Scientific extends partnership with Symphogen to support biopharma
Medical Device | March 01, 2022

Thermo Fisher Scientific extends partnership with Symphogen to support biopharma

Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments


Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
News | February 28, 2022

Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion

BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets


China’s NMPA accepts supplemental NDA for Carteyva
Drug Approval | February 28, 2022

China’s NMPA accepts supplemental NDA for Carteyva

The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China


Unichem receives ANDA approval for bipolar disorder drug
Drug Approval | February 28, 2022

Unichem receives ANDA approval for bipolar disorder drug

Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches


BDR Pharma launches enzalutamide in 160 mg strength
Biotech | February 28, 2022

BDR Pharma launches enzalutamide in 160 mg strength

This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage


Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
News | February 28, 2022

Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr

Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business